Navigation Links
New Report 'Looking at Chiral Technologies' Analyzes the Global,Market Growth Forecasts Driven By Two Very Important Components as,Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c60415) has announced the addition of Looking at Chiral Technologies to their offering.

The advancements in molecular research and continued untiring efforts of the research industry to develop better more precisely applicable Pharmaceuticals as well as agro compounds would have not been possible without the advent of Chiral technologies and their applications.

The usage of chiral molecules is at the very centre of this technological revolution when coupled with the application of chiral technologies as: Chiral Pool, Resolution, Biocatalysts, or asymmetric analysis creates the required compounds. The majority of development activity is routed through fine chemical companies which are additionally trying to upgrade their capabilities in order to provide to the entire portfolio of pharmaceutical drugs for application in the consumer arena.

Such ramping up of operations by companies in order to develop and upgrade basic molecules for wide ranging applications is also bringing the focus of chiral technologies into the development of clinical cures.

This report - Looking at Chiral Technologies - introduces the concept of Chiral Technologies supplementing it with its variants and explaining the actions undertaken by the industry towards developing such compounds jointly and deriving common benefits of clinical nature. The report also analyzes the global market growth forecasts driven by two very important components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals which are synthesized in bulk nature which are contributing to deriving drug streams worldwide.

The report explains the sales of Single Enantiomer pharma on a YOY basis, which is being controlled by certain regulatory constraints. The report also presents an insight on the synergies developed by the industr y majors by building long term partnerships as well as sustaining healthy competition which will lead to the development of the industry as a whole.

The market for Chiral Technologies has been demarcated by end user applications in this report further to which the report provides a future perspective on the industry outlook for Chiral Technologies.

Content Outline:

A. Executive Summary

B. Understanding the Chiral Concept

C. Industry Profile

D. Different Chiral Models for Flexible Markets

E. Intellectual Property Issues

F. Bringing the Molecule to a Commercial Scale - Issues & Challenges

G. How the Pharma Industry is Driving Chiral Technologies

H. Market Demarcations by Chiral Applications

I. Chiral Technology Industry - Future Perspective

J. Major Market Players

K. Appendix

L. Glossary of Terms

Companies Mentioned:

- Altus Biologics Inc

- Ascot Fine Chemicals

- Avecia

- Bachem

- Callery Chemical Company

- Cambrex Corporation

- Catalytica Inc

- Chemi SpA

- ChiRex

- ChromTech International

- Daicel Chemical Industries Ltd

- Daiso Company Ltd

- Degussa-Huls

- DSM

- Great Lakes Fine Chemicals

- IMI (TAMI)

- Johnson Matthey plc

- Kaneka Corporation

- Lonza Ltd

- Novasep

- Oxford Asymmetry International

- Pfanstiehl Laboratories

- PPG-Sipsy

- Sepracor Inc

- Solvias

- Synetix

- Synthon Chiragenics Corporation

For more information visit http://www.researchandmarkets.com/reports/c60415

Contact

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax: +353 1 4100 980


'"/>




Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... The International ... on the north end of the island close to the town famous for its ... 10th 2016. , “We continue to have an amazing experience in Greece, we ...
(Date:5/6/2016)... ... 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a ... in the Bible about helping to stop cancer. Yisrayl says there are too many suffering ... the health and science industries will pay close attention and take action. The Pastor says ...
(Date:5/6/2016)... OR (PRWEB) , ... May 06, 2016 , ... This ... but for women everywhere. The 17th annual National Women’s Health Week takes ... Office on Women’s Health are combining forces to empower women to make their health ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. co-founder, ... BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid Services ... Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross and ...
(Date:5/5/2016)... ... 2016 , ... Pivot Point Consulting achieved the ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, Depth, ... services for electronic health record (EHR) solutions from Epic Systems Corporation . ...
Breaking Medicine News(10 mins):